Sugi Predict

Sugi Predict / Compounds / SCHEMBL1305579

SCHEMBL1305579

SCHEMBL1305579

CCOP(=O)(CC(=O)c1ccccc1)OCC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.59
▸ LMNA P02545 2/20 0.59
▸ MAPT P10636 4/20 0.50
▸ MAPK1 P28482 3/20 0.50
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.44
▸ NR1I2 O75469 1/20 0.44
▸ KCNH2 Q12809 1/20 0.43
▸ GSK3B P49841 2/20 0.42
▸ TRPA1 O75762 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734845 0.84 POLB (0.57) POLBLMNAMAPTMAPK1MEN1
SCHEMBL14105717 0.84 ALDH1A1 (0.49) POLBLMNAMAPTMEN1KMT2A
SCHEMBL28005057 0.83 POLB (0.56) POLBLMNAMAPTMAPK1MEN1
SCHEMBL5734842 0.81 POLB (0.73) POLBLMNAMAPTMAPK1MEN1
SCHEMBL1670924 0.81 HDAC3 (0.53) LMNAMAPTMAPK1KMT2ANPC1
SCHEMBL7900085 0.81 POLB (0.44) POLBLMNAMAPTMAPK1MEN1
SCHEMBL28005428 0.81 TSHR (0.55) POLBLMNAMAPTMAPK1MEN1
SCHEMBL514913 0.79 NFE2L2 (0.43) POLBLMNAMAPTMAPK1MEN1
SCHEMBL2902839 0.79 NR1I2 (0.42) POLBLMNAMAPTMAPK1MEN1
SCHEMBL29169511 0.79 L3MBTL1 (0.56) LMNAMAPTMAPK1NPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400793-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. 2024-12-05 — — US claimed
EP-4396271-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF Momentive Performance Materials Inc. (US) 2024-07-10 — — EP claimed
WO-2023034354-A1 COMPOSITION FOR POLYURETHANE FOAM, FOAM PREPARED THEREFROM AND A METHOD THEREOF MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2023-03-09 — — WO claimed
US-8062816-B2 Phosphonate hole blocking layer photoconductors XEROX CORPORATION (US) 2011-11-22 — — US claimed
US-8053151-B2 Phosphonate containing photoconductors XEROX CORPORATION (US) 2011-11-08 — — US claimed
US-20100101651-A1 POLYMER SOLAR CELLS INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2010-04-29 — — US claimed
EP-2141545-A1 Phosphonate containing photoconductors Xerox Corporation (US) 2010-01-06 — — EP claimed
US-20090325091-A1 PHOSPHONATE CONTAINING PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-12-31 — — US claimed
US-20090297967-A1 PHOSPHONATE HOLE BLOCKING LAYER PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-12-03 — — US claimed
EP-2128709-A1 Phosphonate Hole Blocking Layer Photoconductors Xerox Corporation (US) 2009-12-02 — — EP claimed
EP-4663636-A2 TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BioCryst Pharmaceuticals, Inc. (US) 2025-12-17 — — EP disclosed
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-28 — — US disclosed
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-08-14 — — US disclosed
EP-4180424-B1 SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2025-06-25 — — EP disclosed
US-20250101003-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS LARIO THERAPEUTICS LIMITED (GB) 2025-03-27 — — US disclosed
EP-0646007-A1 NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONES AS 5-g(a)-REDUCTASE INHIBITORS. MERCK & CO INC (US) 1995-04-05 — — EP disclosed
EP-0572166-A1 New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors MERCK & CO. INC. (US) 1993-12-01 — — EP disclosed
WO-1993023050-A1 NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1993-11-25 — — WO disclosed
WO-1993023039-A1 SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1993-11-25 — — WO disclosed
WO-1993023420-A1 NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS MERCK & CO., INC. (US) 1993-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270171-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 POLB 3911/4885LMNA 998/4885MAPT 2984/4885
US-20250257040-A1 HUMAN PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 POLB 3911/4885LMNA 998/4885MAPT 2984/4885
US-20250101003-A1 SPIROCYCLIC CAV2.3 ANTAGONISTS CACNA1A, CACNA1E, CACNA1S POLB 3386/4885LMNA 747/4885MAPT 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.